Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3866MR)

This product GTTS-WQ3866MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3866MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5898MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ5530MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ8753MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ7804MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-HIV
GTTS-WQ3975MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ9604MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ9269MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ2604MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 557
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW